ArticlePediatric dermatology
Utility of Blood Biomarkers for Assessing Atopic Dermatitis Severity in Infants Aged < 2 Years.
Article in Pediatric dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtopic dermatitis (AD) is an increasingly common skin disease that can lead to serious morbidity in a subset of more severely affected infants. Thymus and activation-regulated chemokine (TARC) and squamous cell carcinoma antigen 2 (SCCA2) are biomarkers. This study examined how severity, defined by Patient-Oriented Eczema Measure (POEM) score, correlates with TARC, SCCA2, total immunoglobulin E (IgE), and eosinophil counts in infantile AD (< 2 years), comparing their diagnostic performance and examining each biomarker's association with individual POEM items.
methodsThis retrospective study included 50 children aged < 2 years with newly diagnosed AD (March 2023-November 2024). Patients were categorized as mild or moderate-to-severe disease based on POEM scores. Receiver operating characteristic (ROC) analyses were used to assess each biomarker's sensitivity and specificity for severity classification, and correlations with POEM's seven items were evaluated using Spearman correlations.
resultsSCCA2 had the highest diagnostic accuracy for mild AD (area under the curve [AUC] = 0.708), while TARC had the best performance (AUC = 0.717) for moderate AD. Total IgE and eosinophil counts had AUC values at approximately 0.5. TARC showed stronger correlations (Spearman's rank correlation coefficient [rs] ≥ 0.4) with bleeding and flaking compared with SCCA2.
conclusionsIn children aged < 2 years with AD, TARC and SCCA2 were superior to total IgE or eosinophils in assessing severity. Both TARC and SCCA2 appear valuable for evaluating AD severity; a symptom-specific biomarker selection may facilitate earlier diagnosis and targeted therapy. Larger prospective studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.